The BioPharm Brief: Dual Targets, Treg Therapy, Tumor Responses

Jun 16, 09:04 PM
Headliner
Share
Subscribe

Early clinical data highlight advances in bispecific antibodies and immune modulation, with new findings in Type 2 inflammatory diseases, alopecia areata, and platinum-resistant ovarian cancer.

Share
Subscribe
Next
The BioPharm Brief: Hormones, Metabolism, Momentum
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief